Pharma’s Digital Directive: Not If, But How

The transformative potential of the digital revolution is apparent. However, pharma companies need to think pragmatically about how digital applies to what they already do. 


Learn More

Bionest Partners is a global consulting firm focused on Pharma, Biotech, Medical Device and Diagnostics.

Learn More

Curing What Ails Alzheimer’s Drug Development

Biomarkers will be key to winning the race to a successful Alzheimer’s drug, as we present in our latest In Vivo article.


Learn More

One-Shot Curative Treatments: A Pharma and Payer Revolution

Learn More

Orphans Should Live Alone

Read our recent article for In Vivo with advice for pharma interested in rare diseases.


Learn More

How Immuno-Oncology Is Turning Biomarker Development On Its Head


This In Vivo article covers the challenges in orchestrating a biomarker program in immuno-oncology.


Learn More

New Big Data Initiatives in Oncology

Read our take on the emerging field of ‘Real-time Oncology’ – the ability to constantly monitor changes in a patient’s disease and adjust treatment accordingly.

Learn More

About Bionest

We help clients navigate complex product development and commercialization issues in order to drive growth, create value and gain competitive advantage. We also offer our expertise and analytic skills to support investors with due diligence assignments. Our deep content experience, combined with our collaborative and hands-on approach results in practical solutions that drive internal alignment at the corporate, portfolio, and brand levels.

News & Views

Check out our blog for news and commentary on the latest issues in pharma.